leisure time -WSS

leisure time

author：knowledge 2025-09-06 01:59:36 - browse：8

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Biotech stock slump in 2023: awaiting the turnaround

hotspot

focus

WSS

EpiPen alternative approval delay highlights citizen petition issue

Why are Kaiser Permanente staff considering a strike?

How AI helped researchers track recovery from depression

How digital therapeutics firms are pivoting after Pear's bankruptcy

Biotech stock slump in 2023: awaiting the turnaround

How digital therapeutics firms are pivoting after Pear's bankruptcy

hotspot

leisure time

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

How Vertex's cystic fibrosis drug is changing patients' lives

Trump demands the U.S. pay no more for drugs than other countries … again

Changes to biosimilar regulatory framework must prioritize patients

Moonlake's readout produced a cash windfall. Risks remain

NIH director takes cautious approach to Biden drug pricing priority

Drug repurposing or repositioning? The language matters

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Virginia high school admissions case could be legal follow

Hearing on Medicare drug price negotiation gets unusually heated

leisure time

Biotech stock slump in 2023: awaiting the turnaround

My yearlong odyssey to get my son’s ADHD medication covered

eGenesis tests gene

What Congress can do to address the rural doctor shortage

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Hearing on Medicare drug price negotiation gets unusually heated

entertainment

hotspot

focus

focus